Beta
ManageSearchChatDiscover
331468

Prognostic factors, lines of treatment, and outcome of relapsed pediatric lymphoblastic lymphoma in Children Cancer Hospital Egypt

Article

Last updated: 04 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

Anti-cancer Immunotherapy

Abstract

Background: Pediatric patients with relapsed lymphoblastic lymphoma (LBL) have poor prognoses [1]. This study aims to evaluate the prognostic factors, chemotherapy used, the role of HSCT, and the survival outcome of relapsed pediatric LBL. This retrospective study included 38 relapsed pediatric patients out of 295 patients (12.8%) with LBL in CCHE from July 2007 to July 2020. The median follow-up period was 59.4 months. Males were 68.4% of the study patients, with a median age of 9.3 years.

All patients received acute lymphoblastic leukemia St. Jude total XV protocol initially, patient's gender, pathological subtype, initial stage, central nervous system or bone marrow infiltration, and early response to induction treatment did not have an impact on relapse-free survival. Early relapse was documented in 89.47% of patients with 3y OS 5.8% and was 75% for late relapsed patients with a P-value of 0.01. Hematological or CNS relapse did not affect the outcome of the patients. Seventeen (44.7%) patients received FLAG-M as a salvage protocol with 3y OS 0%, and re-induction R16 was given to 17 (44.7%) patients with 3y OS 17.6%, with significant P-value. Sixteen (42%) patients had complete response post 2nd line therapy with 3y OS 31.2%, but 34.4% developed 2nd relapse, then 84.4% of patients died of active disease. Allogenic BMT was done for only 2 patients with a P-value of 0.1. In conclusion, early relapse and poor response to salvage chemotherapy worsen the outcome of relapsed pediatric LBL; giving re-induction R16 protocol, followed by allogeneic HSCT, improves the outcome.

DOI

10.21608/jcbr.2023.249962.1321

Keywords

Pediatric, Lymphoblastic lymphoma, relapse, refractory disease

Authors

First Name

Samah

Last Name

Semary

MiddleName

FA

Affiliation

Department of oncology, Beni-Suef University, Beni-Suef, Egypt. Depaetment of pediatric oncology, Children Cancer Hospital Egypt

Email

samahsemary@yahoo.com

City

-

Orcid

0000-0002-5394-3307

First Name

Hanaa

Last Name

Rashad

MiddleName

-

Affiliation

department of pediatric oncology, Children's cancer hospital Egypt

Email

hanaa.rashad@57357.org

City

-

Orcid

-

First Name

Sonya

Last Name

Soliman

MiddleName

-

Affiliation

Department of Clinical Pathology, National Cancer Institute (NCI), Cairo University, Egypt Department of Clinical Pathology, Children’s Cancer Hospital Egypt (CCHE-57357), Cairo, Egypt

Email

sonya.soliman@57357.org

City

-

Orcid

-

First Name

Nahla

Last Name

Elsharkawy

MiddleName

-

Affiliation

Department of Clinical Pathology, National Cancer Institute (NCI), Cairo University, Egypt Department of Clinical Pathology, Children’s Cancer Hospital Egypt (CCHE-57357), Cairo, Egypt

Email

nahla.elsharkawy@57357.org

City

-

Orcid

-

First Name

Naglaa

Last Name

Elkinaai

MiddleName

-

Affiliation

Department of Pathology, National Cancer Institute, Cairo University, Egypt Department of Pathology, Children Cancer Hospital Egypt, Egypt

Email

naglaa.elkinaai@57357.org

City

-

Orcid

-

First Name

Eman

Last Name

Nageb

MiddleName

-

Affiliation

Department of Pathology, National Cancer Institute, Cairo University, Egypt Department of Pathology, Children Cancer Hospital Egypt, Egypt

Email

eman.nageb@57357.org

City

-

Orcid

-

First Name

Iman

Last Name

Zaky

MiddleName

-

Affiliation

Department of Radiodiagnosis, National Cancer Institute, Cairo University, Egypt Department of Radiodiagnosis, Children Cancer Hospital Egypt, Egypt

Email

iman.zaky@57357.org

City

-

Orcid

-

First Name

Amr

Last Name

Elnashar

MiddleName

-

Affiliation

Department of Clinical Research, Children Cancer Hospital Egypt, Cairo, Egypt

Email

amr.elnashar@57357.org

City

-

Orcid

-

First Name

Asmaa

Last Name

Hamoda

MiddleName

-

Affiliation

Department of Pediatric Oncology, National Cancer Institute Cairo University. Department of Pediatric Oncology Children Cancer Hospital Egypt 57357

Email

asmaahamoda82@hotmail.com

City

-

Orcid

-

Volume

7

Article Issue

4

Related Issue

44567

Issue Date

2023-12-01

Receive Date

2023-11-20

Publish Date

2023-12-01

Page Start

37

Page End

44

Print ISSN

3009-6391

Online ISSN

3009-7312

Article File

JCBR_Volume 7_Issue 4_Pages 37-44.pdf

PDF . 1.0MB

Link

https://jcbr.journals.ekb.eg/article_331468.html

Detail API

https://jcbr.journals.ekb.eg/service?article_code=331468

Order

331,468

Type

Original Article

Type Code

885

Publication Type

Journal

Publication Title

Egyptian Journal of Cancer and Biomedical Research

Publication Link

https://jcbr.journals.ekb.eg/

MainTitle

Prognostic factors, lines of treatment, and outcome of relapsed pediatric lymphoblastic lymphoma in Children Cancer Hospital Egypt

Details

Type

Article

Created At

30 Dec 2024